JPEN Journal Club 25. Study Design

Affiliations

Comment

Ronald L Koretz. JPEN J Parenter Enteral Nutr. 2017 Feb.

. 2017 Feb;41(2):263-265.

doi: 10.1177/0148607116679787.

¹ 1 Olive View-UCLA Medical Center, David Geffen-UCLA School of Medicine, Sylmar and Los Angeles, California, USA.

No abstract available

Keywords: critical reading; elafibranor; gastroenterology; metabolic syndrome; nonalcoholic fatty liver disease; obesity.

Comment on

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Clinical Trial.